Similarly, combinatory treatments with CpG-Stat3 siRNA and PD-1 antibody in A20 lymphoma tumor-bearing mice led to significantly higher percentages of activated CD8+ T cells positive for IFNγ, CD107α, which measures T cell cytotoxicity, and GZMB at the tumor sites (Figures 2D–2F). This evidence concerns the gene CD8A and lymphoma.